GLP-1 Receptor Agonists in Heart Failure
Biomolecules · 02.10.2025 · 15 (10) · 1403
DOI: 10.3390/biom15101403 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 02.10.2025. Verfasst von Ali Reza Rahmani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY 11790, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Heart Failure, Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF) is a growing public health concern, driven by the increasing prevalence of obesity, diabetes, and aging. Despite therapeutic advances, HF continues to be associated with high morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for glycemic control in type 2 diabetes, have demonstrated cardiovascular benefits in clinical trials. Recent studies, including STEP-HFpEF and SUMMIT, have shown improvement in symptoms and weight loss in patients with HF with preserved ejection fraction (HFpEF). GLP-1 RAs are involved in multiple biological pathways relevant to heart failure pathophysiology. These include pathways related to sympathetic nervous system activity, inflammatory cytokine signaling, oxidative stress, calcium handling, natriuretic peptide signaling, and cardiac metabolism. GLP-1 receptor agonists modulate vascular pathways involving nitric oxide signaling, endothelial function, and renal sodium handling, contributing to improved hemodynamics and neurohormonal balance. Together, these actions intersect with key neurohormonal and cellular processes contributing to chronic heart failure progression. This review explores the mechanistic overlap between GLP-1 receptor signaling and heart failure pathophysiology. This mechanistic overlap suggests a plausible role for these agents as adjunctive treatments in heart failure, especially in metabolically driven phenotypes. While direct cardiac effects remain incompletely defined, systemic metabolic and anti-inflammatory actions provide a mechanistic basis for observed clinical benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY 11790, USA.
- Division of Cardiology, Department of Pediatrics, Columbia University Irving Medical Center, New York, NY 10032, USA.
- Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11790, USA.
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
- Health Sciences Center, Stony Brook University Medical Center, Stony Brook, NY 11794, USA.
ORCID-Profile: Ali Reza Rahmani, Andreas Kalogeropoulos
Zitieren
APA
Rahmani, A. R., Dhaliwal, S. K., Pastena, P., Kazakov, E., Jayaseelan, K., & Kalogeropoulos, A. (2025). GLP-1 Receptor Agonists in Heart Failure. Biomolecules, 15(10), 1403. https://doi.org/10.3390/biom15101403
Vancouver
Rahmani AR, Dhaliwal SK, Pastena P, Kazakov E, Jayaseelan K, Kalogeropoulos A. GLP-1 Receptor Agonists in Heart Failure. Biomolecules. 2025;15(10):1403. doi:10.3390/biom15101403
BibTeX
@article{Rahmani2025,
author = {Rahmani, Ali Reza and Dhaliwal, Simrat Kaur and Pastena, Paola and Kazakov, Eliot and Jayaseelan, Keerthana and Kalogeropoulos, Andreas},
title = {GLP-1 Receptor Agonists in Heart Failure},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {10},
pages = {1403},
doi = {10.3390/biom15101403}
}
EUVIMED